Biliary Atresia

Biliary Atresia is a topic covered in the Select 5-Minute Pediatrics Topics.

To view the entire topic, please or purchase a subscription.

5-Minute Clinical Consult (5MCC) app and website powered by Unbound Medicine helps you diagnose and manage 900+ medical conditions. Exclusive bonus features include Diagnosaurus DDx, 200 pediatrics topics, and medical news feeds. Explore these free sample topics:

5-Minute Clinical Consult

-- The first section of this topic is shown below --



Biliary atresia (BA) is a congenital disease characterized by fibrosis, obstruction, and obliteration of the biliary system that is universally fatal without intervention.


  • BA accounts for approximately 30% of cases of neonatal cholestasis.
  • BA is the most common cause of persistent cholestasis in infants and children and the most frequent indication for pediatric liver transplantation.
  • The disease affects 1:8,000 to 1:18,000 live births.

Risk Factors


  • No single genetic mutation has been identified as the sole cause of BA, and there is no clear pattern of inheritance.
  • Genes influencing morphogenesis may contribute to pathophysiology.


  • Biliary obstruction begins at, or near, the time of birth and progresses throughout early infancy, leading to damage and ultimately scarring of liver parenchyma.
  • Approximately 20% of biliary patients have at least one other major congenital anomaly (i.e., embryonal form) including splenic malformation, interrupted inferior vena cava, midline liver, situs inversus, preduodenal portal vein, and intestinal malrotation.
  • More common form is the perinatal form that is not associated with malformations.


Etiology is not completely defined, but many different pathogenic mechanisms have been proposed, including the following:

  • Perinatal infection of the liver and biliary tract with potential organisms including cytomegalovirus, rotavirus, and reovirus
  • Immune dysregulation
  • Defective morphogenesis
  • Environmental toxin exposure
  • Vascular insufficiency

-- To view the remaining sections of this topic, please or purchase a subscription --